Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Trigeminal Neuralgia Treatment Market from 2024 to 2025?
The market for trigeminal neuralgia treatment has seen robust growth in the past few years. The industry’s expansion is forecasted to continue, increasing from $0.68 billion in 2024 to $0.73 billion in 2025, representing a compound annual growth rate (CAGR) of 7.1%. The historic growth is mainly due to the rise in chronic diseases, the surge in neurological disorders, the escalating cases of trigeminal neuralgia, the increased preference for minimally invasive treatments, and the growing demand for minimally invasive surgeries.
What Is the Projected Market Size of the Trigeminal Neuralgia Treatment Market?
In the coming years, the market size for treatment of trigeminal neuralgia is anticipated to experience robust growth, expanding to $0.95 billion by 2029 with a 6.7% compound annual growth rate (CAGR). The growth during the forecast period can be ascribed to growing awareness of trigeminal neuralgia among medical professionals as well as the wider public, an uptick in TN instances, a growing aging populace, escalating healthcare costs, and the rising count of diagnosed cases. Forefront trends pertinent for the forecast period comprise enhancements in neuromodulation methods, advancements in TENS technology, progress in medical investigation and technology, the acceptance of minimally invasive surgical procedures, and evolution in digital health technologies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21307&type=smp
Who are the Major Competitors in the Trigeminal Neuralgia Treatment Market Outlook?
Major companies operating in the trigeminal neuralgia treatment market are Aetna Inc., Thermo Fisher Scientific Inc., Novartis AG, Sandoz, Sun Pharmaceutical Industries Ltd., Apotex Inc., Lupin Limited, Taro Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Kriya Therapeutics, Convergence Pharmaceuticals Limited, Noema Pharma AG, Max Healthcare, Initiator Pharma AS, Coda Biotherapeutics Inc., Oxford Cannabinoid Technologies Holdings Plc, NanoVibronix, Biogen Idec, Shanghai SIMR Biotechnology Co. Ltd., Capnia Inc.
What Is Fueling Growth in the Trigeminal Neuralgia Treatment Market?
The augmenting instances of neurological disorders are set to enhance the expansion of the trigeminal neuralgia treatment market. Neurological disorders are a collection of conditions impacting the nervous system, encompassing the brain, spinal cord, and nerves. The rising instances of these disorders can be chalked up to a variety of reasons such as genetic predisposition, infections, trauma, toxins, autoimmune reactions, and degeneration. Treatment for trigeminal neuralgia offers support for neurological patients by alleviating severe facial pain, mitigating nerve irritation, improving life quality, enabling pain management, and averting additional neurological damage. For example, data from the European Brain Council, a non-profit organisation based in Belgium, in April 2022, reveals more than 600 neurological diseases and nearly 300 psychiatric conditions impacting millions worldwide, including 65 million individuals with epilepsy. In Europe, dementia affects 10.5 million people, with estimations showing that this figure may ascend to 18.7 million by 2050. Hence, the escalating instances of neurological disorders are anticipated to stimulate the growth of the trigeminal neuralgia treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21307&type=smp
Which Trigeminal Neuralgia Treatment Market Segments Are Growing the Fastest?
The trigeminal neuralgia treatment market covered in this report is segmented –
1) By Treatment Type: Medications, Surgery, Other Treatment Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Medications: Anticonvulsants, Muscle Relaxants, Antidepressants
2) By Surgery: Microvascular Decompression Surgery, Gamma Knife Radiosurgery, Rhizotomy
3) By Other Treatment Types: Nerve Blocks, Stereotactic Radiosurgery, Physical Therapy
Which Industry Trends Are Shaping the Future of the Trigeminal Neuralgia Treatment Market?
Leading firms in the field of trigeminal neuralgia treatment are concentrating on the submission of investigational new drug (IND) applications with the aim of securing regulatory approval and enlarging their market penetration. An IND application is a method through which a drug manufacturing company seeks the green light from regulatory bodies to commence the testing of a newly developed drug in humans, with the objective to determine its safety, efficacy, and suitable dosage. For instance, Noema Pharma, a clinical-stage biotech company based in Switzerland, was given an IND application by the Food and Drug Administration (FDA), an American government agency, for LibraTN in February 2022, granting it permission to start a Phase 2b clinical trial of mGluR5 inhibitor NOE-101 for trigeminal neuralgia (TN). LibraTN is a 24-week, multicenter, placebo-controlled study designed to evaluate the effectiveness and safety of NOE-101 in TN-affected adults and it’s anticipated to deliver reports in the first half of 2024. Additionally, the FDA extended a fast track designation for basimglurant (NOE-101) to speed up its development and examination process.
Access The Full Report Here:
Which Countries Are Leading the Trigeminal Neuralgia Treatment Market?
North America was the largest region in the trigeminal neuralgia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the trigeminal neuralgia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21307
This Report Delivers Insight On:
1. How big is the trigeminal neuralgia treatment market, and how is it changing globally?
2. Who are the major companies in the trigeminal neuralgia treatment market, and how are they performing?
3. What are the key opportunities and risks in the trigeminal neuralgia treatment market right now?
4. Which products or customer segments are growing the most in the trigeminal neuralgia treatment market?
5. What factors are helping or slowing down the growth of the trigeminal neuralgia treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model